Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives

Jin，Hongliang1; Gong，Yani1; Cheng，Lin2; Zhu，Yuanmei1; Zhang，Zheng2; He，Yuxian1

2024

10.3390/v16010036

Viruses   影响因子和分区

1999-4915

LCB1 is a computationally designed three-helix miniprotein that precisely targets the spike (S) receptor-binding motif (RBM) of SARS-CoV-2, exhibiting remarkable antiviral efficacy; however, emerging SARS-CoV-2 variants could substantially compromise its neutralization effectiveness. In this study, we constructed two multivalent LCB1 fusion proteins termed LCB1T and LCB1T-Fc, and characterized their potency in inhibiting SARS-CoV-2 pseudovirus and authentic virus in vitro. In the inhibition of various SARS-CoV-2 variants, the two LCB1 fusion proteins exhibited markedly improved inhibitory activities compared to LCB1 as anticipated; however, it was observed that relative to the D614G mutation hosting variant, the variants Delta, Lambda, and Omicron BQ.1.1, XBB, XBB.1.5, and EG.5.1 caused various degrees of resistance to the two fusion proteins’ inhibition, with XBB, XBB.1.5, and EG.5.1 variants showing high-level resistance. Moreover, we demonstrated that bat coronavirus RaTG13 and pangolin coronavirus PCoV-GD/PCoV-GX were highly sensitive to two LCB1 fusion proteins, but not LCB1, inhibition. Importantly, our findings revealed a notable decrease in the blocking capacity of the multivalent LCB1 inhibitor on the interaction between the virus’s RBD/S and the cell receptor ACE2 when confronted with the XBB variant compared to WT and the Omicron BA.1 variant. In conclusion, our studies provide valuable insights into the antiviral profiling of multivalent LCB1 inhibitors and offer a promising avenue for the development of novel broad-spectrum antiviral therapeutics.

drug resistance LCB1 multivalent inhibitor receptor binding motif (RBM) SARS-CoV-2

SCI

英语

其他

CAMS Innovation Fund for Medical Sciences[2022-I2M-1-021] ; China Postdoctoral Science Foundation[2021M690458] ; Shenzhen Science and Technology Program[JCYJ20210324131606018] ; Guangdong Science and Technology Plan Project, Construction of high-level biosafety laboratories[2021B1212030010] ; National Natural Science Foundation of China["82230076","82221004","82151212"]

Virology

Virology

WOS:001151180800001

MDPI

2-s2.0-85183277789

Scopus

1.NHC Key Laboratory of Systems Biology of Pathogens,Institute of Pathogen Biology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,102600,China
2.Institute of Hepatology,National Clinical Research Center for Infectious Disease,Shenzhen Third People’s Hospital,The Second Affiliated Hospital,School of Medicine,Southern University of Science and Technology,Shenzhen,518112,China

Jin，Hongliang,Gong，Yani,Cheng，Lin,et al. Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives[J]. Viruses,2024,16(1).

Jin，Hongliang,Gong，Yani,Cheng，Lin,Zhu，Yuanmei,Zhang，Zheng,&He，Yuxian.(2024).Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives.Viruses,16(1).

Jin，Hongliang,et al."Susceptibility and Resistance of SARS-CoV-2 Variants to LCB1 and Its Multivalent Derivatives".Viruses 16.1(2024).